Biotechnology companies face ethical challenges of two distinct types: bioethical challenges faced on Abstract account of the nature of work in the life sciences, and corporate ethical challenges on account of their nature as commercial entities. The latter set of challenges has received almost no attention at all in the academic literature or media. This paper begins to remedy that lacuna, examining ethical issues that arise specifically on account of the status of biotech companies as commercial entities. The focus here is on three representative issues: product safety, corporate social responsibility, and corporate governance. It is argued that each of these issues poses particular ethical challenges for companies in the biotech sector. In the area of product safety, it is noted that biotech companies face particular challenges in determining what counts as a 'safe' product, given the contentious nature of what might count as a 'harm' in the biotech field. In the area of corporate social responsibility, the adoption of a 'stakeholder approach' and an attempt to manage the social consequences of products pose special challenges for biotech companies. This is due to the enormous range of groups and individuals claiming to have a stake in the doings of such companies, and the trenchant controversies over just what the social consequences of various biotechnologies might be. In the area of corporate governance, biotech companies need to seek out and follow best practices regarding the ways in which information, authority, and influence flow between a company's shareholders, managers, and Board of Directors, if they are to avoid duplicating the ethical and financial scandal that brought down ImClone. An important meta-issue, here -one that renders each of these corporate ethical challenges more vexing -is the difficulty of finding the appropriate benchmarks for ethical corporate behavior in a field as controversial, and as rapidly evolving, as biotechnology. Three programmatic suggestions can be made: Firstly, scholars and others interested in the ethical performance of the biotech sector must seek out and build opportunities for richer interdisciplinary collaboration. Secondly, companies within the biotech sector must seek out expertise and build capacity and competency in dealing with the corporate ethical issues that arise in their sector. Finally, companies in the biotech sector should explore the opportunities for collective problem solving afforded by the existence of local, national, and international industry associations such as the Biotechnology Industry Organization, BIOTECanada, and EuropaBio.
Torn Between Two Worlds
there is a market, and (ii) thereby producing a profit for their owners. Companies in the biotechnology industry -like others in the As inhabitants of two worlds, biotech companies face a doublelife sciences -inhabit at once two different domains. On one hand, barreled array of ethical issues. One set of issues stems from the biotech companies are part of the healthcare system. The products involvement of biotech companies in the life sciences and the and processes they develop often have as their aim the improvehealthcare system; the kinds of ethical issues that most readily ment of human health, the lessening of human pain, and the spring to mind when the topic of ethics in biotechnology arises. forestalling of human deaths. On the other hand, biotech compaThese include the now-familiar front-page issues such as the moral nies are also commercial ventures. That is, they are legal entities status of human gametes and human fetuses, the permissibility of that function by marshaling capital and human resources with the germ-line genetic modification, [1] and whether cloning threatens interrelated goals of (i) producing a product or service for which what it means to be human. [2, 3] Also included under this general ness is to increase profits; [4] and (ii) the attempt to explain ways in which businesses can honor the legitimate claims of shareholders heading are further issues that are less likely to grab headlines, but and other investors, while at the same time paying due attention to that are none the less familiar to those with more than a passing the needs and rights of customers, employees, and neighboring knowledge of bioethics, including issues related to research on communities. human subjects (consent, harm-benefit ratios, etc.), confidentiality, and the effects of genetic information on the lives of individuals For whatever reason, business ethics issues that arise in the and communities.
field of biotechnology have received surprisingly little attention 1 . For as long as biotechnology has been a question of public A second set of ethical issues is faced by biotech companies on concern, 'ethical issues in biotechnology' has been a topic account of their status as commercial ventures. Issues here include 'owned' by bioethics (and, to a lesser extent, by environmental ethics in marketing and advertising, workers' rights (or labor ethics). This has meant that a large number of ethical issues critical relations more generally), environmental issues, issues related to to the biotech industry, including product safety and corporate corporate governance and investor relations, social accountability, governance issues, have been effectively excluded from the agenand issues associated with carrying out business in foreign counda because they are largely beyond the ken of bioethics, as that tries. Of course there is, in this list, nothing unique to the biotech field has traditionally been understood 2 . industry: to an extent, biotech companies face the same ethical At this point, individuals not familiar with the relevant academchallenges as are faced by companies in any other sector of the ic literature may be perplexed. 'Bioethics'…'business etheconomy. These issues comprise the field of business ethics -the ics' …what's the difference? It's all about ethics, isn't it? Fair study of ethical issues that arise in commercial ventures of all enough. The distinction is, to a degree, artificial -a question of an kinds. But for biotech companies, business ethics has a somewhat arbitrary distinction drawn between two academic disciplines. Yet different flavor, or spin, owing to the uniqueness of the products there is a significant degree of differentiation between the two these companies produce and the services they provide.
fields. They are studied, for the most part, by different people. The topic under discussion here is this second set of ethical They are written about in different journals, and in different books. challenges, namely those that biotech companies face by virtue of But biotech spans the two. And a number of the specific ethical their status as commercial enterprises. These challenges have issues that arise with regard to commercial biotechnology are in historically proven particularly difficult for business ventures of fact quite foreign to the sorts of considerations and frameworks all kinds. The scandals involving Enron, WorldCom, ImClone, that flow from the field of bioethics. So attending here to the and others are among the more recent 'sentinel events' that have corporate ethical issues that arise in biotech is part of an attempt to focused attention on corporate ethics. But a quick look at headlines fill a gap in our practical and theoretical understanding of the over the past few decades reminds us of the many major news ethical challenges faced in that industry. stories that turned into business ethics case studies: the Ford Pinto, the Exxon Valdez, Dow Corning breast implants, and Union 2. Corporate Ethical Issues Carbide's disaster at Bhopal, to name a few. In each case, we see evidence of corporate executives and other employees choosing poorly when asked to choose between profit and ethics. But this In this section, three key issues of corporate ethics, namely tension -between obligations to shareholders and obligations to product safety, corporate social responsibility, and corporate govothers -is not found only in these notorious cases. It is a tension ernance, are examined as they relate to biotechnology companies endemic to the world of business. And the field of business ethics as commercial entities. In each case, the primary considerations has historically had as its primary concerns: (i) the attempt to found in the business ethics literature are outlined, and the notable refute the claim, most famously voiced by Nobel Prize-winning differences, if any, in the form that the issue takes within the economist Milton Friedman, that the only responsibility of busidomain of biotechnology versus in other industries are discussed. for such a use of its discoveries, even if the company had no direct back at least several decades. The old standard of caveat emptorrole in the terrorist acts in question. ' let the buyer beware' -is now generally recognized as defunct.
Brenkert's second point is philosophical: he argues that there is Corporations are recognized as having a duty of care with regard indeed good ethical grounding for this emerging legal standard, to both the obvious and the non-obvious safety-related aspects of that is, the idea that a manufacturer might be morally responsible their products. This duty is recognized as extending well beyond for distant harms caused by uses of a product remote from the the requirements of law and regulation. [6] Of course, it is widely manufacturer's sphere of direct control. The implication is that the recognized that no product is without risk: almost any product, if trend towards application of the stringent standard implied by the used wrongly, can result in injury. Because of this fact, "questions social products liability doctrine is not just happening: it is indeed of safety are essentially questions of acceptable and known levels happening for good reasons. Briefly, if companies produce a of risk". [7] The operative question, then, is whether a given compaproduct that, in the current social context, may foreseeably conny has taken sufficient care to make sure that known risks assotribute to undesirable outcomes, and if those companies make ciated with their products are made clear to consumers; and that specific choices that contribute to, rather than mitigating, those their product is reasonably free of dangerous defects. The question harms, then it is at least prima facie reasonable that they be held of what counts as 'sufficient' care is, of course, a difficult one, but collectively responsible for (some portion of) the resultant harms. the concept at least provides a framework within which to evaluate And with the weight of good reason on its side, the social products the extent of a corporation's obligation.
liability doctrine can reasonably be expected to continue to gain More recently, a higher standard has emerged within the literaground. Of course, to say that there are good reasons to support ture with regard to the responsibility of manufacturers for their this doctrine is not to conclude the debate. But the fact it is even products. Brenkert [8] calls this the 'social products liability' docadvanced as plausible should make it clear that issues such as trine. According to this doctrine, the manufacturer of a product whether a pharmacogenomics corporation should be held responmay be held responsible for harms caused by that product, even if sible for distant, marginally foreseeable consequences of its disthe product is in no way defective and even if the harm caused was coveries are precisely the sort of business ethics issues with which not the result of some activity over which the manufacturer had biotech companies, and industry organizations, must increasingly direct control. The particular focus of Brenkert's own discussion is develop competency. the putative responsibility of (at least some) gun manufacturers for Indeed, for the field of biotechnology, product safety is a (at least some) deaths caused by their products. Brenkert argues special concern, both ethically and strategically. No company that, if such responsibility is plausible, it must be so because four wants to face the public relations disaster that Monsanto encounconditions are met, namely: (i) significant harms have occurred; tered in relation to the marketing of genetically modified seeds and (ii) the actions of gun manufacturers (e.g. in their marketing foods. [9] This fear makes product safety management a crucial strategies) contributed to those harms; (iii) those harms and their strategic consideration. Beyond pragmatic questions of good pubconnection to the manufacturer's marketing practices were forelic relations, the ethics of product safety is an exceptionally seeable; and (iv) there were alternative courses of action open to challenging issue for biotech companies. Generally speaking, the industry and its member companies.
firms engaged in health research and the provision of healthBrenkert makes two key points about the social products liabilirelated products and services are seen as being subject to very high ty doctrine. The first is observational. Brenkert observes that, as a ethical standards. Nowhere are ethical and legal standards for matter of fact, manufacturers in many industries are being held to product safety more exacting than in fields related to human this higher standard. The lesson for biotech companies is that, health. rightly or wrongly, the possibility exists that corporations in the biotech sector (to extend Brenkert's own argument) might be held
To complicate things further, it may be difficult -indeed, responsible for the uses to which the technologies they develop are impossible -to define what counts as a 'safe' product in the field put. For example, it might someday come about that a of biotechnology. At least some of the dangers attributed to pharmacogenomics firm is held responsible for a terrorist act made genetically modified foods by opponents of those products are possible by its discovery of a genetic susceptibility, concentrated dangers that are impossible to quantify and perhaps even difficult to define. Think, for example, of the claim that antibiotic-resisThe adoption of a stakeholder management perspective, as part tance genes (sometimes used as markers of genetic transformaof a CSR strategy, may pose particular challenges for biotech tion) might spread from genetically modified plants to other orcompanies. In particular, it can be very difficult to establish just ganisms, [10] or the claim that cloning threatens what it means to be who should be counted among a biotech company's stakeholders. human. [2] The very measures according to which such risks should Indeed, this is a problem for stakeholder theory in general. A be judged are the subject of serious debate. This difficulty, comcentral question in the literature relates to whose interests should bined with the growing significance of the social products liability have influence on managerial decisions, and how much? Biotech doctrine, means that it may be exceedingly difficult for biotech companies face special challenges in this regard, as their stock-incompanies in particular to seek out and follow appropriate stantrade includes the very building blocks of all life -DNA, RNA, dards and policies when it comes to product safety. decision-making and sliding into paralysis, constitutes a very obligations to the communities of which they are a part. CSR is a serious -and under-explored -challenge for biotech companies. multi-faceted (and contested) concept. We will focus on two of its A second relevant facet of CSR has to do with a corporation's facets here.
willingness to attend to the social consequences of its products. In First, attention to CSR can be taken to imply a willingness to this regard, the socially responsible investment movement, for attend to the needs of a wider range of stakeholders than has example, has supported a move away from investment in such historically been the case for business corporations in general.
socially problematic industries as the arms, tobacco, gambling, According to adherents of what has come to be known in business and alcohol industries. For many, the concern about these induscircles as 'stakeholder theory', stakeholders are "those groups who tries is not about individual instances of consumers using these can affect, or who are affected by, the activities of the firm". [11] products. The worry, rather, is that these industries are producing Stakeholder theory (or, more generally, the stakeholder approach) products that, when used by millions of customers, may have seeks substantive ways to acknowledge that a wider range of socially undesirable effects. That is, the social consequences of parties are crucial to the success of the firm, and that many of these widespread smoking, drinking or gambling may include harms not parties might in fact be owed serious, concrete, moral obligations.
captured by examining individual behavior. The stakeholder approach -at least, those elements that suggest Corporations can attend to the social consequences of their that attention to a broad range of stakeholders is not merely wise products and services in a number of ways. Some companies take but morally mandatory -has become enormously popular, if action to mitigate the acknowledged negative social implications somewhat contentious. Critics charge that the multiple lines of of their products. Some tobacco companies, for example, now accountability implied by acknowledging a multiplicity of stakeproduce anti-smoking literature aimed at teens. Other companies holders reduces efficiency, [12] and that indeed the very idea of refuse entirely to sell certain products or services. Case in point: stakeholders as morally significant undermines the morally-signifmany American sporting-goods retailers now refuse to sell fireicant relationship between corporate executives and stockholdarms. And hospitals, in many jurisdictions, refuse to permit fetal ers.
[13] Critics also note that the stakeholder approach is incapable sex-selection, on the grounds that the associated devaluation of of guiding necessary improvements in corporate governance. [14] females (given that female fetuses are more often aborted in such The financial catastrophes at Enron, WorldCom, and ImClone scenarios) is socially pernicious. were all failures of corporate governance -that is, failures of the way organizations and institutional incentives were structured, Attending to the social consequences of their products poses resulting in failures of corporate behavior to align with corporate special challenges for biotech companies, because the social congoals and policies. Such failures will surely not be made less sequences of many biotech products and services are the subject of likely, according to critics of stakeholder theory, if lines of acserious debate. For example, many biotech companies, as well as countability are multiplied. (Norman and Heath, unpublished manmany scientists, have already foresworn one significant biotechuscript). [15] nology, namely reproductive cloning. For these companies and scientists, as well as for a very significant proportion of the general But the ImClone scandal was, in a sense, relatively minor; the public, the social consequences (however ill defined) of cloning costs to the public were 'merely' financial. But in the field of are simply unacceptable. So with regard to cloning, industry and biotech, it's easy to imagine failures in governance with much the public are (generally) on the same page. But other topics more worrisome consequences, both for public safety and for the engender greater disagreement. The social implications of adlong-term reputation of the industry. Imagine, for example, a CEO vanced assisted reproductive technologies (and the special burden of a biotech company engaged in the development of a new form they represent for women), or of the development of drugs of gene therapy, deciding to slant (or even falsify) data submitted targeted to specific privileged (or under-privileged) ethnic groups, to the relevant regulatory bodies. Imagine the Board knowing are as yet unclear. Biotech companies wishing to be socially about this, and failing to rein in the rogue CEO, because members responsible, in the sense of attending to the social implications of of the Board stand to profit from the short-term inflation of stock their products and services, face serious challenges, not the least of prices that would follow regulatory approval of the new therapy. which is determining just what the social implications of those Such a failure of corporate governance -rooted at least partly in products and services are (or may one day be).
faulty structuring of Board compensation -could have disastrous consequences both for patients and for stockholders. Governance issues won't necessarily look dramatically differ-
Issue 3: Corporate Governance
ent at biotech companies than at other companies. Two factors do warrant mention, however. First, many biotech companies are The Enron and Arthur Andersen scandals brought the question founded by scientist-entrepreneurs, many of whom won't have a of corporate governance into the limelight. Indeed, there is reason detailed knowledge of management, let alone knowledge of stateto expect that corporate governance will be the key paradigm for of-the-art corporate governance structures, or the niceties of securboth the theory and practice of business ethics for at least the next ities regulations. Secondly, the rate of change and the financial several years. Corporate governance systems are, roughly speakpressures of the biotech industry may encourage companies to ing, the systems by which corporations are directed and controlled.
play fast-and-loose with the rules. The short timeline often experiSuch systems include the policies and procedures that determine enced from making a scientific discovery (perhaps at a university how information, authority, and influence flow between a comlab), forming a spin-off commercial enterprise, acquiring venture pany's shareholders, managers and Board of Directors. From the capital and making an Initial Public Offering, through to product point of view of business ethics, governance is about who has the development and commercialization, may simply be inconsistent right to determine the appropriate courses of action for a corporawith careful planning of governance structures. Slowing down tion, and how that right gets translated into actual corporate long enough to find clarity about how best to direct the business of behavior.
the company in the interests of stockholders (with suitable attenThe biotechnology industry had its own high-profile brush with tion to the public good) may not be easy, but it is nonetheless governance issues in the ImClone scandal. In October 2002, crucial. Samuel Waksal, founder and former CEO of ImClone Systems, pleaded guilty to criminal charges including securities fraud, perjury, bank fraud, and obstruction of justice. In short, Waksal had 3. Searching for Guidance: Ethics Benchmarking in used his knowledge of an impending negative decision by the US the Biotech Industry FDA concerning ImClone's new cancer drug, cetuximab, to profit Perhaps the most general way of describing the ethical chalin ways forbidden by American securities regulations. The crimilenge faced by companies in the biotech industry is by reference to nal charges laid point to individual culpability; but the real lesson the notion of benchmarking. for the biotech industry lies in the larger failure of corporate governance evidenced at ImClone. ImClone's Board of Directors,
Benchmarking is the process of determining who within a given for example, whose role it is to represent and protect the interest of field is the very best, who sets the standard for excellent performshareholders, failed miserably at this task when they turned a blind
ance, and what that standard is. As it pertains to corporate ethics, eye to Waksal's forgery and fraud. Once they got wind of the benchmarking involves assessing hot key issues and surveying trouble that was brewing, the members of the Board sold enough one's industry and relevant stakeholders to determine which comshares to devalue ImClone's publicly-traded stock, just prior to the panies are 'getting it right'. In this regard, biotech companies face FDA's critical decision. a very serious ethical challenge. It is difficult, if not impossible, to determine within the field of biotech who sets the standard and 4. Conclusion what that standard is. The simple reason is that within biotech, standards of ethical performance are even more hotly contested
The goal of the present paper has been to introduce readers to a than they are in other, more traditional industries.
set of ethical challenges that biotech companies face not by virtue of their status as life-science enterprises, but by virtue of their Where can biotech firms look to for the relevant benchmarks? It status as commercial enterprises. No claim has been made that seems trite at this juncture to point out that the science of biotechbiotech companies are fully unique in this regard; the claim has nology is advancing so rapidly that legal and ethical frameworks merely been that, to date, too much discussion about ethical issues can scarcely keep pace. None the less, it is of course not entirely in biotechnology has been carried out with disregard for the fact true to say that corporate decision-making takes place in a vacuthat biotech research, development, and commercialization is oftum; indeed, there exists a fairly wide range of national and en done in a corporate context. [18] Biskepticism is where enquiry begins; in itself, it does not solve hard otech companies are also subject to various bits of national legislaproblems. tion. For example, Canadian biotech companies are subject to such
The first three quarters of a decade of intensive public attention pieces of Canadian legislation as the Patent Act, [19] the Plant to the world of biotechnology (beginning roughly with the birth of Breeders' Rights Act, [20] and, provided it passes the necessary Dolly, the world's first cloned mammal, in 1996) was dominated parliamentary hurdles, the new Act Respecting Assisted Human by discussion of bioethical issues. Is cloning 'unnatural'? Is germReproduction (expected to be made law sometime during line gene therapy too dangerous? When does human life begin? Is 2004).
[21] Finally, biotech companies may also be subject to (or individual consent to genetic testing for familial diseases suffiperhaps, more accurately, guided by) the industry's own guidecient? The next decade will see -indeed, must see -increased lines, as embodied in the Statement of Ethical Principles adopted attention to corporate ethics in the world of biotech. As biotech by the Biotechnology Industry Organization (BIO) [22] and BIOTEmoves from a realm of speculative science to a realm of serious Canada, [23] and EuropaBio's Statement of Ethical Values. [24] commercial enterprises, ethical reflection on that realm must shift So, on the face of it, it would be false to say that the biotech as well. In a world of commercial biotechnology, questions of industry lacks guidance. But still, it seems fair to suggest that there corporate ethics, including questions related to product safety, is not much ethical certainty in this area. International conventions CSR, and corporate governance, will increasingly come to domion biotechnology are open to -indeed, they are in need ofnate the field of biotech ethics. national and local interpretation and contextualization. National
Once we are collectively aware of this second set of ethical laws such as Canada's Patent Act are notorious for the awkwardchallenges, and the vast body of related literature made available ness with which their terms apply to the living things that make up by scholars in the field of business ethics, what way forward is the biotech industry's stock in trade. And although the industry is available? I conclude with three brief and programmatic suggesto be applauded for having taken steps to develop its own guidetions. lines, those guidelines are far from providing precise roadmaps Firstly, scholars and others interested in the ethical performthrough treacherous moral terrain. So extant industry-wide ethics ance of the biotech sector must seek out and build opportunities for guidelines, while a step in the right direction, will not always richer interdisciplinary collaboration. Biotech is already a richly provide adequate direction. Given the fact that public opinion interdisciplinary field; biotech ethics is even more so. Yet the regarding the moral standing of various biotechnologies is argument here suggests that including scholars from the field of mercurial and often ill-informed, and that the opinion of experts in business ethics will return greater dividends still. law and ethics is similarly deeply divided, one can be forgiven for Secondly, companies within the biotech sector must seek out wondering where even well-intentioned biotech companies can expertise and build capacity and competency in dealing with the look to for reliable guidance.
corporate ethical issues that arise in their world. Enhancing capa-
